Works matching IS 21641153 AND DT 2018 AND VI 8 AND IP 1

Results: 22

Imfinzi First Treatment Approved to Reduce Disease Progression in Unresectable Stage III NSCLC After Chemoradiation.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 50
Publication type:: Article

Erleada First Therapy Approved for Patients with Nonmetastatic Castration-Resistant Prostate Cancer.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 50
Publication type:: Article

Zytiga Receives New Indication, with Prednisone, for Metastatic, High-Risk Castration-Sensitive Prostate Cancer.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 49
Publication type:: Article

Lutathera First Radioactive Drug Approved for Adults with Gastroenteropancreatic Neuroendocrine Tumors.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 49
Publication type:: Article

Gilotrif Receives New Indication as First-Line Treatment for Metastatic NSCLC with Nonresistant EGFR Mutations.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 48
Publication type:: Article

Lynparza First Treatment Approved for Patients with Germline BRCA-Positive Metastatic Breast Cancer.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 48
Publication type:: Article

The Cost of Hematopoietic Stem-Cell Transplantation in the United States.

Published in:

Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 40

By:

Broder, Michael S.;
Quock, Tiffany P.;
Chang, Eunice;
Reddy, Sheila R.;
Agarwal-Hashmi, Rajni;
Arai, Sally;
Villa, Kathleen F.

Publication type:

Article

Aplastic Anemia in a Patient with Anaplastic Oligodendroglioma Postradiation and Concurrent Temozolomide Therapy: Case Report and Review of the Literature.

Published in:

Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 34

By:

Hanna, Kirollos S.;
Mancini, Robert;
Burtelow, Matthew;
Bridges, Benjamin

Publication type:

Article

The Value of Pre-FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers.

Published in:

Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 31

By:

Fendt, Peter R.;
Ung, Brian;
Vogenberg, F. Randy

Publication type:

Article

Prevention of Thromboembolism in Patients with Multiple Myeloma.

Published in:

Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 26

By:

Gerardo, Nicole

Publication type:

Article

Encouraging Efficacy and Safety with Enasidenib or Ivosidenib plus Azacitidine in Patients with Newly Diagnosed AML.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 25
Publication type:: Article

Safety and Tolerability of Midostaurin from Expanded Treatment Protocol in Patients with FLT3 Mutation-Positive, Newly Diagnosed AML.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 25
Publication type:: Article

Enasidenib Monotherapy Is Well-Tolerated and Active in Older Patients with Untreated mIDH2 AML.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 24
Publication type:: Article

Nivolumab plus Azacitidine Shows Encouraging Activity in R/R AML or as Frontline Therapy in Elderly Patients with AML.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 24
Publication type:: Article

Median 3.5-Year Follow-Up of Ibrutinib Treatment in Patients with...

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 23
Publication type:: Article

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 23
Publication type:: Article

Adverse Events, Resource Use, and Economic Burden in Patients with Mantle-Cell Lymphoma in the United States.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 23
Publication type:: Article

Median 3.5-Year Follow-Up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle-Cell Lymphoma: A Pooled Analysis.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 22
Publication type:: Article

Preliminary Results of Prophylactic Tocilizumab After Axicabtagene Ciloleucel (axi-cel; KTE-C19) Treatment for Patients with Relapsed/Refractory, Aggressive NHL.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 22
Publication type:: Article

Phase 2 Study of Brentuximab Vedotin plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma.

Published in:: Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 22
Publication type:: Article

Microbial Growth of Single-Dose Antineoplastic Drug Vials at 28 Days.

Published in:

Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 17

By:

Pritchard, Elizabeth R.;
Waddell, J. Aubrey;
Crane, Brad J.;
Porter, Amy M.;
Roberts, Susan;
Yates, Danielle M.;
Thomas, Angelia M.

Publication type:

Article

Impact of Pharmacist-Driven Educational Intervention on Documentation of Bowel Function Assessment in Patients with Cancer Who Are Using Opioids.

Published in:

Journal of Hematology Oncology Pharmacy, 2018, v. 8, n. 1, p. 13

By:

Flynn, Kimberly N.;
Gochett, Celestine

Publication type:

Article